Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma.
Fridley BL, Dai J, Raghavan R, Li Q, Winham SJ, Hou X, Weroha SJ, Wang C, Kalli KR, Cunningham JM, Lawrenson K, Gayther SA, Goode EL. Fridley BL, et al. Among authors: weroha sj. Cancer Epidemiol Biomarkers Prev. 2018 Sep;27(9):1101-1109. doi: 10.1158/1055-9965.EPI-17-0728. Epub 2018 Jul 2. Cancer Epidemiol Biomarkers Prev. 2018. PMID: 29967001 Free PMC article.
Genes associated with bowel metastases in ovarian cancer.
Mariani A, Wang C, Oberg AL, Riska SM, Torres M, Kumka J, Multinu F, Sagar G, Roy D, Jung DB, Zhang Q, Grassi T, Visscher DW, Patel VP, Jin L, Staub JK, Cliby WA, Weroha SJ, Kalli KR, Hartmann LC, Kaufmann SH, Goode EL, Shridhar V. Mariani A, et al. Among authors: weroha sj. Gynecol Oncol. 2019 Sep;154(3):495-504. doi: 10.1016/j.ygyno.2019.06.010. Epub 2019 Jun 14. Gynecol Oncol. 2019. PMID: 31204077 Free PMC article.
ECPPF (E2F1, CCNA2, POLE, PPP2R1A, FBXW7) stratification: Profiling high-risk subtypes of histomorphologically low-risk and treatment-insensitive endometrioid endometrial cancer.
Gonzalez-Bosquet J, Weroha SJ, Bakkum-Gamez JN, Weaver AL, McGree ME, Dowdy SC, Famuyide AO, Kipp BR, Halling KC, Yadav S, Couch FJ, Podratz KC. Gonzalez-Bosquet J, et al. Among authors: weroha sj. PLoS One. 2022 Dec 1;17(12):e0278408. doi: 10.1371/journal.pone.0278408. eCollection 2022. PLoS One. 2022. PMID: 36454788 Free PMC article.
The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer.
Serebrenik AA, Argyris PP, Jarvis MC, Brown WL, Bazzaro M, Vogel RI, Erickson BK, Lee SH, Goergen KM, Maurer MJ, Heinzen EP, Oberg AL, Huang Y, Hou X, Weroha SJ, Kaufmann SH, Harris RS. Serebrenik AA, et al. Among authors: weroha sj. Clin Cancer Res. 2020 Jul 1;26(13):3397-3407. doi: 10.1158/1078-0432.CCR-19-2786. Epub 2020 Feb 14. Clin Cancer Res. 2020. PMID: 32060098 Free PMC article.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
Kanakkanthara A, Kurmi K, Ekstrom TL, Hou X, Purfeerst ER, Heinzen EP, Correia C, Huntoon CJ, O'Brien D, Wahner Hendrickson AE, Dowdy SC, Li H, Oberg AL, Hitosugi T, Kaufmann SH, Weroha SJ, Karnitz LM. Kanakkanthara A, et al. Among authors: weroha sj. Cancer Res. 2019 Dec 1;79(23):5920-5929. doi: 10.1158/0008-5472.CAN-19-1405. Epub 2019 Oct 16. Cancer Res. 2019. PMID: 31619387 Free PMC article.
80 results